| Ferrous iron-dependent pharmacology RL Gonciarz, EA Collisson, AR Renslo Trends in pharmacological sciences 42 (1), 7-18, 2021 | 34 | 2021 |
| Emerging role of ferrous iron in bacterial growth and host–pathogen interaction: New tools for chemical (micro) biology and antibacterial therapy RL Gonciarz, AR Renslo Current opinion in chemical biology 61, 170-178, 2021 | 24 | 2021 |
| Selective ablation of primary and paracrine senescent cells by targeting iron dyshomeostasis TD Admasu, K Kim, M Rae, R Avelar, RL Gonciarz, A Rebbaa, ... Cell Reports 42 (2), 2023 | 22 | 2023 |
| Antimalarial trioxolanes with superior drug-like properties and in vivo efficacy BR Blank, RL Gonciarz, P Talukder, J Gut, J Legac, PJ Rosenthal, ... ACS infectious diseases 6 (7), 1827-1835, 2020 | 22 | 2020 |
| Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors H Jiang, RK Muir, RL Gonciarz, AB Olshen, I Yeh, BC Hann, N Zhao, ... Journal of Experimental Medicine 219 (4), e20210739, 2022 | 21 | 2022 |
| In vivo bioluminescence imaging of labile iron in xenograft models and liver using FeAL-1, an iron-activatable form of D-luciferin RL Gonciarz, H Jiang, L Tram, CL Hugelshofer, O Ekpenyong, I Knemeyer, ... Cell Chemical Biology 30 (11), 1468-1477. e6, 2023 | 5 | 2023 |
| A tandem activity-based sensing and labeling strategy reveals antioxidant response element regulation of labile iron pools AT Pezacki, RL Gonciarz, T Okamura, CD Matier, L Torrente, K Cheng, ... Proceedings of the National Academy of Sciences 121 (28), e2401579121, 2024 | 3 | 2024 |
| Elevated labile iron in castration–resistant prostate cancer is targetable with ferrous iron–activatable antiandrogen therapy RL Gonciarz, S Sakhamuri, N Hooshdaran, G Kumar, H Kim, MJ Evans, ... European journal of medicinal chemistry 249, 115110, 2023 | 3 | 2023 |
| Expanded scope of Griesbaum co-ozonolysis for the preparation of structurally diverse sensors of ferrous iron J Chen, RL Gonciarz, AR Renslo RSC advances 11 (54), 34338-34342, 2021 | 3 | 2021 |
| The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2 RK Suryawanshi, P Jaishankar, GJ Correy, MM Rachman, PC O’Leary, ... bioRxiv, 2024 | 2 | 2024 |
| Exploiting KRAS-driven ferroaddiction in cancer through ferrous iron-activatable drug conjugates (FeADC) H Jiang, RK Muir, RL Gonciarz, AB Olshen, I Yeh, BC Hann, N Zhao, ... bioRxiv, 2020.05. 12.088971, 2020 | 2 | 2020 |
| Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance MT Klope, P Talukder, BR Blank, S Chelebieva, J Chen, SD Fontaine, ... bioRxiv, 2025.01. 02.631109, 2025 | | 2025 |
| Synthesis and In Vivo Profiling of Desymmetrized Antimalarial Trioxolanes with Diverse Carbamate Side Chains MT Klope, JA Tapia Cardona, J Chen, RL Gonciarz, K Cheng, ... ACS Medicinal Chemistry Letters 15 (10), 1764-1770, 2024 | | 2024 |
